NewTimeSpace News: August 04, 2026, HSBC HOLDINGS(00005.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 48.06 billion, decreased by 1.93% YoY
NewTimeSpace News: August 04, 2026, HARBOUR CENTRE(00051.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 705 million, increased by 7.8% YoY
NewTimeSpace News: Continental Aerospace Technologies Holdings Limited (00232.HK) announced that its indirect wholly-owned subsidiary CAT US entered into a settlement agreement with the US Department of Justice on 31 July 2026 over PPP loans obtained during the pandemic. The entity will pay USD11,772,680.14 plus interest accruing at an annual rate of 4% commencing on 23 June 2026. The settlement does not constitute an admission of liability or wrongdoing by CAT US.
NewTimeSpace News: ALPHAMAB ONCOLOGY announced on August 4 that its wholly-owned subsidiary Jiangsu Alphamab entered into a licence agreement with Pathos AI for JSKN016. Pathos AI is granted exclusive rights to research, develop, manufacture and commercialise JSKN016 globally excluding mainland China, Hong Kong, Macau and Taiwan. The upfront payment amounts to US$125 million, with total milestone payments reaching up to US$2.093 billion.
NewTimeSpace News: CARsgen Therapeutics announced on August 4 that CT0596, the Company’s allogeneic CAR-T cell product targeting BCMA, has obtained IND approval from the NMPA for the treatment of patients with relapsed/refractory multiple myeloma.
NewTimeSpace News: Jiangsu Guofu Hydrogen Energy Equipment announced on August 3 that the procedures for converting 18,416,758 domestic shares of the Company into H-shares were completed on the same day. The converted H-shares will be listed on the Hong Kong Stock Exchange starting from August 4, 2026.
NewTimeSpace News: Youzan Technology Limited announced on August 3 that it expects to record a net profit of approximately RMB65 million to RMB72 million for the six months ended June 30, 2026, compared with RMB73 million in the same period last year.
NewTimeSpace News: Shaanxi Micot Pharmaceutical Technology announced on August 3 that the Phase II clinical trial of its self-developed candidate drug MT200605 for the treatment of acute ischemic stroke has achieved the primary efficacy endpoint.
NewTimeSpace News: Alphamab Oncology (09966.HK) announced that JSKN033, a high-concentration subcutaneous fixed-dose combination consisting of HER2 bispecific ADC and PD-L1 immune checkpoint inhibitor, has obtained approval from CDE of NMPA to initiate a Phase III clinical study (Trial No. JSKN033-301) as monotherapy for recurrent or metastatic cervical cancer refractory to platinum-based chemotherapy and PD-1/PD-L1 inhibitors. JSKN033 is the world’s first such high-concentration subcutaneous injectable combination product.
NewTimeSpace News: Hangzhou SF Intra-city Industrial Co., Limited (09699.HK) released a positive profit alert. It expects profit attributable to owners of the Company for the first half of 2026 to be no less than RMB301 million, representing a year-on-year increase of no less than 120%; adjusted net profit to be no less than RMB240 million, rising by no less than 50% year-on-year; revenue to be no less than RMB11.669 billion, a year-on-year growth of no less than 14%.
NewTimeSpace News: IMAGI INT'L (00585.HK) announced that the board lot size for its shares will be changed from 8,000 shares to 500 shares, effective 9:00 a.m. on 24 August 2026. Based on the closing price of HK$3.68 per share on the announcement date, the market value per board lot will drop from HK$29,440 to HK$1,840. The Board believes the arrangement will enhance share liquidity and broaden the shareholder base.
NewTimeSpace News: Touyun Biotech Group Limited (01332.HK) announced that Ms. Zhou Ruijuan has been appointed as Executive Director and Vice Chairman with effect from 3 August 2026, responsible for the development of the Group’s new materials business. Ms. Zhou holds a Bachelor’s Degree in Management from Lanzhou University and possesses over ten years of senior management experience in the technology and data service industries.
NewTimeSpace News: Guangzhou Innogen Pharmaceutical Group Co., Limited (02591.HK) announced that two contract manufacturing sites in China for Isupaglutide α Injection have passed compliance inspection conducted by Brazil’s ANVISA in accordance with PIC/S GMP standards and obtained relevant GMP certificates, confirming that the production and quality management systems comply with PIC/S GMP requirements.
NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the Phase Ib/II clinical trial (SYS6090-008) evaluating the combination therapy of SYS6090 Injection for colorectal cancer developed by the Group has officially been initiated at the first study centre in China. The product is a recombinant fully human anti-PD-1 fusion protein fused with IL-15, classified as Class 1 therapeutic biological product.
NewTimeSpace News: Ascletis Pharma Inc. (01672.HK) announced that once-daily oral small-molecule GLP-1 ASC30 has obtained FDA clearance to initiate global Phase III clinical studies. Two pivotal trials will be conducted in the United States, Europe and Canada, enrolling approximately 4,600 obese or overweight subjects. Meanwhile, the Company disclosed first-in-class oral small-molecule GLP-1/GIP/amylin triple-target fixed-dose combination (FDC) achieved up to 15.2% weight loss in non-human primates, representing a relative improvement of 120% compared with the dual-target formulation.
NewTimeSpace News: August 03, 2026, WUXI APPTEC(02359.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 28.9 billion, increased by 38.94% YoY。
